ࡱ> gdefnvц]d B1PNG  IHDRPgAMAܲ pHYs  JIDATxQ#u{ xްWwA2q՚0]*?)t$%_CDuZ]3gffoGZkMuuYd+~ i昙zLk:uptUUƠ1?4_=m|}r }@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@>djffjYW~ iZSkn Su cfkTE왙c=1{myefk xݧλ~=]]{s\ԾUӗ _U 3;׵G ^Ӆ)@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@k~d~Tԅk~]WOwlݽͥW*ibolyT]vwPI~i@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@G1]U53GOiSU=kpYzAUo.S5.&Yj=cjs+{4SUVuOϪKto' ;_chfVU]6znݷGվm{y:>d}Y5_T޶g*p:{}Wo['*&[@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88ݫfG>~?Vm"5s U5.9w8~G3mt%>ND'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq>ztwUWuѣ.׮]o[omK WtEmtUE:ZvਪW혪U}z8S]!8VUw]T?8T_6kzͅ p5U=3W=Ry75Wtx7U3uG*"'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88  Npq@'88ݏckQ>k G~,IENDB`n: ;۝:|D>\YPNG  IHDRPgAMAܲ pHYs  IDATx]IQ3vy=htHe_x=^VFcǖ*cVT՜6or;9&bΊ9:̸q:>].c|v9FF/IfD#W>Ǭ-uk(s1gT̪ͪǬ/8.lgc{#2bqq9>]""zo ހ:烪GE?菬YmΪ9sjUǬW{ŮA={k~5Ƽ5I]GdmfQ`;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8ހ&sVEYGTor4Ock78.*j:ΣP|8|ss^9_󨦫K5.Ɍ̎tK5UWIULű}k_lٯUocWt)a##"f\]C6gDԭH""*}J\@fFEUY綹V8ꘙ]wʊ5Yut55|q#2"YQ1M5wԜyMx6*|#[u|vM_=\/F:M\e =PU]k#""j_;6M"VvNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8>{ 92fgo?23"2#G:2#""3;wTEDdDUE={kQiW9߶nUɌ\?zʈ+;2~1jf:#^Iߍ➶-63pv^ W;zk?o93Vs4NNtfZ}Y#Dӫۍg ?Qyw1ɲV8!hyxϋ}ϑYUᶷLcz1Qz=|dX|F̶ל%Lj12c0ZuU#b\2f<#[_yC3ڮpx]7?Gq ׇ֜׳w=Dk2"#gTvWpn"*뭖̈U~MoĈxי Nm9uv|+yPUdV+ЈvNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vYm3k3^K""3gEFUګ#猚Ȍ1F;hΊK̪s04rqWUeσ*"+26 ?#ZU7gsG5XyTUTE͊̌?пku98fFh93.d:bVͪfۓ?#oTDV4*۬Ǹj+#<+/ކZsƺ5z\7gUsz9+3n}#Oo+6tRy?|6|_g˸WWk3nu㒍wKED\Ǹq=賷ͪ^ix=2"nyˈQQ#""僡t^\/ ?As\cָdf\G%̀ȑh|tE\+1u+un[/:TEsY%rVUUȦGג_FrY٣ɯsކ%bfefшX ̓c텊Z2ֳnVϮ}eʳ>;2;X 4^-?yǶ}tz[[=o/UW9 r}5:s~ѿAAm[>l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8ހ&#"*[*"fC߁<4¹22"b}{V̌\jj\pWkUoGZG5qFDDԬ1ׯC9S-jȑ뇈靖̬}?F_?q&8k333jV:>|xq^wMkd:Mrd^̨532Cu#:,^V8z~U9geVջn]ND=U4mwGDdEF̨8n2*Fv=_b:k{8"̗Y^SœYYs3<{~]s;_gVY5"+*}hFdTqs Mz 1K5_>ϾGwRu1rTFx)W81TU3^LqɼdZDe䈪9Z>P9?LjwT:Gڎc#DFFE:*ƈzrsVͣ*\ڨ;8"c#?r/KpD1:QcU>,~"#*xz 9oofD8Y~ukuLcZ8߶ʳ7ͨ\oު{SƫOQUrl޿fȾKo/8Uy+9Q|$E雏A~R;G?=5s!#vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp `;l'8vNp]Wf=w3~ǜM=UQxG|VE;^ֵ߽|&rx@yVӱȌj~ ȼͭkD4jd>FuQkNsnkP##bmϖȈ̬9k<+_}cF8-ȑ)**{%"jm|'2fuՖu3h*cU\U5gy"ǰ98kj֜+Pu~~i:_x2332*fU ެ_jEdz7df}4~`Mgw_Go$823sޔ_cϳwdE1 {(8gT@F%WŬS:fTETU=ŷ"*yeѱIENDB`ngNEMs֗PNG  IHDR&5bKGD#2gIFg>U cmPPJCmp0712`IDAThCXMhG~)=F0CNS\薆!`R Pz\SR$jZ@K j e7{3Ҭ~"~ثyߛyfgopkMWof Wdi>΋/6 WE-b"#\Y 5̎bV^"۬+{qf/ch:8ԁ_eNeiXg*Ia2d/2@v1ғ8T`G+A>%Xb䤃I 1CL%I1x""x q As$[ߞtUq:qO~Pd/W[pè#0=޷ @Ϙ5^KLj'qOwi[ן@}T-^QچdJ))hM#OJt~d:nf9waB2kRjH*J Gc ߊgpP0:U II7(^OY{k ^ݕRF0p?m'9hD#z&Y+af t\ysŜYNסp*]Q1)9H؏`r@ EZT=e"b>VNTy;g]=نS:+/fDA +_ '30>z?1<+ *'2==Ht|3xl6 Euh'ɂ GɧZ@p(4q^`T]gt\)bhOH&*D˵KGDSGlSG'`K/]!FzIxC6ő$ݢ_NŻW9;U KW.ܒMs,~IENDB`%(    g4jonathan-gilbert@uiowa.eduBmailto:jonathan-gilbert@uiowa.edu.david-hensley@uiowa.edu<mailto:david-hensley@uiowa.eduv"&john-weis@uiowa.edu4mailto:john-weis@uiowa.edu$,mike-kienzle@uiowa.edu:mailto:mike-kienzle@uiowa.edu~&*Pamela-york@uiowa.edu8mailto:Pamela-york@uiowa.edu/ 00DArialans MTra llb0DArial Blackra llb0" DGill Sans Ultra Boldb0"0DGill Sans MTra Boldb0"@ .  @n?" dd@  @@``    ;    6$  ] 2 |](Vj= q& M #?224X^&|++  s >204*;%/(JT& )d tylOQ   l)?/  O"@%*U%*  !2K3 4L67?b$vц]d B1b$;۝:|D>\YB b$gNEMs֗/ 0AA f)))MMM@8  ~" Hʚ;w8ʚ;g4BdBd b0ppp@ <4dddd8i0l g41d1d, b0pq pp<42d2d8i0l<4!d!d8i0l0___PPT10 L___PPT9.&}?  %O  =}New Ventures Formation*-$ Forming New Ventures `New Ventures Fundamentals$ rNew Ventures Fundamentals& Adding new functions at UIRF ":$Technology Formal market screening processes on all inventions Feedback on R&D for commercialization Management Full time internal new ventures development team Entrepreneur-in-residence program Corporate venture partners Technology consulting network Financing Internal  Gap funding- grant commercialization programs New ventures advisors & Ventures Advisory Board Relationships with venture development firms Relationships with Series A venture investors PZP PP PP MMMZ MMM MMM    MMMNew Ventures Positions*  l*Finding New UI Technology Company Concepts++$PREVIOUS Invention disclosure submission to UIRF Faculty or graduate student initiative External firm initiative NEW Request for Proposals (RFP) through UI and UIRF Gap Funds New  seeking function through CEO-in-Residence College Liason seeking function Market feedback to investigators through invention disclosure screening process PhPPPP MMMhMMMbmOpportunity Development  XCompany Development Timeline$ VDisbursed Gap FundsGAP Fund #1 Funds dispersed July  06 $0.6M total (GIVF + UIRF match + PI match) 7 pre-company projects funded Gap Fund #2 Funds dispersed Fall  06 $5.2M total (Battelle + PI match) 8 projects funded; 2-3 other possible companies  ZbZ ZlZ % %&UIRF Role in Top Priority New Ventures''  ~UIRF Board of Directors UI MEMBERS President Gary Fethke President UI Foundation Lynette Marshal VP Doug True VP Jean Robillard VP Meredith Hay Assoc. VP Tom Sharpe Dean Barry Butler Dept Head IM Paul Rothman S. Assoc. Dean Mike Apicella Director JPEC David Hensley Law Professor Mark Janis: PP ))))))>@ f6x$UI Spinout Companies: Who to Contact"%$.The New Ventures Team& /  0` 333MMM` fBtg` 3f3ff___` 3fwww3f%i` 3fZX___i3` XfZX3fmo3` 3f\Iqy`eӢ` f3f3f3fz` Vbr(FwwwKpfܹ` 3f3f$DjQ333` 3f3j33f` ffMMM>>\6X~!p` -\- 5d_/z3f>?" dP@(|?" dd@   " @ ` n?" dd@   @@``PR    @ ` `,p>>  ((  ( ( 6L "P@  T Click to edit Master title style! !$ ( 0 "p@`  RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S ( 04 "`@p  \*   ( 0X "`    ^*   ( 0  "`  ^*   ( c  A.Ndomeword_1line_BLK_SMLDome_wordmark on 1 line - Black -Small"  ( 6P "*## TUIRF4 GMMMGMMMZB ( c $DMMM"VO Vj ( RA޽h ?32slide 3fZX___i3___PPT10i.υD+D=' = @B + @Digital blue design template [1] 0 og ,(  , , 6 ɏ "@   T Click to edit Master title style! ! , 0 "    W#Click to edit Master subtitle style$ $ , 00 "`@  \*   , 06 "`   ^*   , 0: "`@  ^*    ,  A.?Ndomeword_1line_BLK_SMLDome_wordmark on 1 line - Black -Small#" `   , 6> "*## TUIRF4 GMMMGMMMZB , c $DMMM"VO V` , HA޽h ?32 3fZX___i380___PPT10.υD(0 P8(     NQhshs P%   v* F##FFii  Nhshs  %  x* F##FFiid  c $ ?*L  4  NXhshs  0)  RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  Tmhshs P   v* F##FFii  Tqhshs    x* F##FFiiH  0޽h ? 3380___PPT10. 4(  4 4 0( P%   X*  4 0$  %  Z*  4 6l P   X*  4 6    Z* H 4 0޽h ? 3380___PPT10. /{j 0 yPX(  X~ X s *t( 0    ! X s *(`    QDepartment of Chemistry IP & New Ventures symposium March 29nd 2007 BRPI MMM* X 6 p^  jUniversity of Iowa Research Foundation (UIRF) Pamela York Executive Director 5-4311, pamela-york@uiowa.eduk kMMMUH X 0޽h ? 33___PPT10i.0\+D=' = @B +S 0 j b ? (  ~  s *(      s *\(Y  6What do we mean by  new ventures ...? & a technology company that has the features venture capital firms look for:*rP&MMML l  ? #" rT ! <̵?r  |Large market opportunity  typically > $200M total market, or, overall cost basis & investment that can yield 10x ROI Equity based company- provides clear exit strategy for venture investors,;II @`  <?r  f10x return on investment @`  < ?"`w  BPatents, copyrights that provide barriers to entry for competitorsCCII @`  < ?"`w  y+Technology & products that can be protected,, @`    <?r w  NEntrepreneurs seasoned through experience in high technology startup companiesOOI @`   < ?r w  iExperienced management team @``B  0o ?`B  0o ?`B  0o ?`B  0o ?ZB  s *o ?ZB  s *1 ?w w ZB   s *1 ?r r H  0޽h ? 3fZX___i3___PPT10i.P@Go+D=' = @B +s  0   P  (  r  S (P;   2  HԔ  j B  2  NtCԔ"p  B  ~   6G_C"? sL   6 t  GMANAGEMENT TEAM   6z\ Y!PROPRIETARY PRODUCT OR TECHNOLOGY" "2  H Ԕ w X B  ~ @ 6GC"? D  6 '  A FINANCING     BCC"?P HUI INTERNAL FUNCTION   <HS"`?  EEXTERNAL FUNCTION *  6`  The Three Legs of the  Stool for a Venture Backed Technology CompanyF FB  s *޽h ? 3fZX___i3___PPT10i.P@+D=' = @B +} 0 p$(  r  S L%(pp   r  S $&(  H  0޽h ? 3fZX___i3___PPT10i.qEr+D=' = @B + 0 `(  X  00 X  0 0 f  0"`0 pPx  c $8(     "  <<w  k!New Ventures Director In progress." ))) "  <XBR-  cVentures Lead In progress. ))) "  <@E *  Market Analyst R. Penington. )))  "  <L) cConsultative New/Existing.  ))) "  <$R<!  eAdministrative New/existing. ))) "  <W` zE  q'Marketing & Communications New/existing.( ))) "   <\` 7 u+Opportunity Prospecting Coordinator Liaison., $)))"   <`0   fCEO-in-Residence In progress. ))) "   <f  fCEO-in-Residence In progress. ))) L   c $@AE L   c $@Dj @ BGHAIw L  c $ 0 "  <k W` u+Opportunity Prospecting Coordinator Liaison., $)))"  <4q 0w u+Opportunity Prospecting Coordinator Liaison., $)))  0loP d q/* Excluding education, IP management, licensing0 20I  0@ : >UIRF( 2  0I @I.C.E.( 2  0$0`w BColleges ( 2 H  0޽h ?O      3fZX___i3___PPT10i.x+D=' = @B +c0 bbJPWb(    <GNHC"?o C/ x  0C"?  x  0C"? C x  0C"?   6 @C IThe New Ventures Pipeline$  <4P . k#Company Patent Strategy & Execution,$ #GCx  3 BC=DE\F>==2=IIIIIm2mmIm== @     `"6 ?@ {_    6Xf H  ULicense to Existing Co." PG:   3 \T :   3 \T :   3 \T :   3 \T :  3 \T :  3 \[T :  3 \T :  3 \!T :  3 \!.T :  3 \.;T :  3 \;HT :  3 \HVT :  3 \V_T :  3 \_lT :  3 \lyT :  3 \yT :  3 \T :  3 \T :  3 \T :  3 \T :  3 \T :  3 \T :   3 \T : ! 3 \T : " 3 \T : # 3 \T : $ 3 \T : % 3 \!T : & 3 \!*T : ' 3 \*7T : ( 3 \7DT : ) 3 \DQT : * 3 \Q_T : + 3 \_lT : , 3 \lyT : - 3 \yT : . 3 \T : / 3 \T : 0 3 \T : 1 3 \T : 2 3 \T : 3 3 \T : 4 3 \T  5  BCDEFA @\RO 4 6 #   : 7 3   : 8 3   : 9 3   : : 3   : ; 3    : < 3   ! : = 3  ! . : > 3  . < : ? 3  < I : @ 3  I V : A 3  V c : B 3  c l : C 3  l y : D 3  y : E 3   : F 3   : G 3   : H 3   : I 3   : J 3   : K 3   : L 3   : M 3   : N 3    : O 3    : P 3   ! : Q 3  ! . : R 3  . < : S 3  < I : T 3  I V : U 3  V _ : V 3  _ l : W 3  l z : X 3  z : Y 3   : Z 3   : [ 3   : \ 3   : ] 3   : ^ 3   : _ 3   : ` 3   : a 3   : b 3    : c 3    : d 3   ! : e 3  ! * : f 3  * 7 : g 3  7 E : h 3  E R : i 3  R _ 4 j #  _ d  k  BCDEF @` 4 l # _ d : m 3 d q : n 3 q ~ : o 3 ~ : p 3  : q 3  : r 3  : s 3  : t 3  : u 3  : v 3  : w 3  : x 3  : y 3   : z 3   : { 3  " : | 3 " / : } 3 / < : ~ 3 < I :  3 I W :  3 W d :  3 d m :  3 m z :  3 z :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3   :  3   :  3  " :  3 " / :  3 / 8 :  3 8 E :  3 E R :  3 R ` :  3 ` m :  3 m z :  3 z :  3  :  3  :  3  :  3  l  S    :  3  :  3     BC,DEF,z @` 4  # q ? :  3 q ? :  3 q ? :  3 q? :  3 q? :  3 q&? :  3 q&4? :  3 q4<? :  3 q<J? :  3 qJW? :  3 qWd? :  3 qdq? :  3 qq? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q"? :  3 q"/? :  3 q/=? :  3 q=J? :  3 qJW? :  3 qWd? :  3 qdm? :  3 qmz? :  3 qz? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q? :  3 q"? :  3 q"/? :  3 q/8? :  3 q8F? :  3 qFS? :  3 qS`? :  3 q`m? 4  # qmr?    BCDEF @r n: 4  # !mr :  3 !r :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 !" :  3 !"0 :  3 !0= :  3 !=J :  3 !JW :  3 !We :  3 !er :  3 !r :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 !# :  3 !#0 :  3 !0= :  3 !=F :  3 !FS :  3 !S` :  3 !`n :  3 !n{ :  3 !{ :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 ! :  3 !     BCdDEFd @$n :B   3   :   3  <c :   3 Jc :   3 'Wc :  3 2bc :  3 =mc :  3 c :  3 Wc :  3 ec :  3 rc :  3 c :  3 c :  3 c :  3 c :  3 c :  3 c :  3 c :  3 c :  3 c :  3 "c :  3 /c :  3  =c :   3 Jc : ! 3 %Uc : " 3 0`c : # 3 =mc : $ 3 Jzc : % 3 Xc : & 3 ec : ' 3 pc : ( 3 {c : ) 3 c : * 3 c : + 3 c : , 3 c : - 3 c : . 3 c : / 3 c : 0 3 c : 1 3 c : 2 3 +c : 3 3 8c : 4 3 Fc : 5 3 !Qc 4 6 # n#S~ : 7 3  : 8 3  : 9 3  : : 3  : ; 3  : < 3  : = 3  0 > 0  R  Protected  Stand Alone Commercial Technology or Broad IP Platform0C ZBGC ? 0pPY  y-Screening & Evaluation Channels (3-12 Months)0. Z-GC @  BCDEFA @[& ^ E 6GpOH H 0  o#Company Model & Product Development0$ Z#GC I <~9 U IP Protection,  GC:B J@ 3 R&x K 3 BC=DE\F>==2=IIIIIm2mmIm== @     `"6 ?   L 6#[ 6 RWaive UIRF IP Rights" PG M BZG6H+C"?   N 0h'g  aBusiness Model & Team0 ZGC O 0+p Pb  aFinancing & Licensing0 ZGC P 00P  SMonitor0 ZGCB  s *޽h ? 3fZX___i3___PPT10i.0+D=' = @B + 0 P6(  ~  s *t6(@p   x  c $7(p0  H  0޽h ? 3fZX___i3___PPT10i. O+D=' = @B ++ 0 B:0 (  ^"  6Ck x  c $D(,     <M:g "  E Market Screen( 2  <O:g A YP LVentures Development( 2  <T:g  F  KLicense Development( 2  <dX:g p Y  ?License( 2d   <GH>IH A "d  @ <ZG}CH$I}C H { ^   6G H,I Y p{ ^   6G`H2I`Ypp  60]p`p 8UIRF $F  a i -    p`b  0 m - fb  6L a i ! "  Bbf  ZTechnologies & Inventions$ L  c $  6d n 6Technology Industry Business Viability Licensing Terms<7 &I  6 t@  IEXTERNAL EXPERTS:   6~b P )Technology Industry Management Investors,* )I  6D0  IEXTERNAL EXPERTS: $F  a i -   9 `b  0 m - fb  6L a i ! B  s *޽h ?_     3fZX___i3___PPT10i.QS+D=' = @B +[ 0  %px(  p p S (><$0   B p s *D` ` ,$D02 p 0 . ,$@02 p 0  ,$@02 p 0  ,$@02 p 0  ,$@02  p 0 d ,$@0  p 6)dC"? ,$0 NResearch & Development 2  p 6)@C"?  },$ 0 JProduct Definition 2 p 6C"?ssZ,$ 0 GProduct Testing 2 p 6<C"? 2,$ 0 KProduct Development 2 p 6\C"?r,$ 0 E Product Sales 2 p 0C"? 0 " ,$@ 0 G TASK TIMELINE 2 p 0(fC"?  ,$0 FResearch Grant 2f p 0fC"?  ,$0 D UI Gap Funds 2 f p 0@fC"?H ,$0 gAngel SBIR STTR.0 F2f fI p 0fC"?   ,$0 GVenture Capital 2f p 0Ļ<  ,$0 fLoans Buyouts Public Markets 0 <2fIB p 0Df  ,$@02 p 0f5 0 ,$@02 p 0f>  ,$@02 p 0f> ,$@02 p 0fM  ,$@02 p 0fP f ,$@0   p 0ȉfC"?@`,$@0 Y$$ INTO COMPANY. 2ff "p 6͉\C"?pP ,$D0 [!Most gap funded projects are here"( 2" %p 6|҉ ,$0 ~2UI  Venture Philanthropy "0 F2fIP p s *޽h ?"` 3fZX___i3^DVD___PPT106D.OP+MxD@' = @B D}@' = @BA?%,( < +O%,( < +D' =%(D' =%(D@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD' =%(Db' =%(D3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<* p%(D' =-o6Bdissolve*<3<* pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<* p%(D' =-o6Bdissolve*<3<* pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<* p%(D' =-o6Bdissolve*<3<* pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD' =%(D' =%(D@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*"p%(D' =-o6Bdissolve*<3<*"pD' =%(D' =%(D@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD3' =4@BB BB%(D' =1:Bvisible*o3>+B#style.visibility<*p%(D' =-o6Bdissolve*<3<*pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<* p%(D' =-o6Bdissolve*<3<* pD@' =A@BB BB0B%(D' =1:Bvisible*o3>+B#style.visibility<*%p%(D' =-o6Bdissolve*<3<*%p+H+0+p0 ++0+ p0 ++0+ p0 ++0+p0 ++0+p0 ++0+p0 ++0+p0 ++0+p0 ++0+p0 ++0+p0 ++0+p0 ++0+p0 ++0+ p0 ++0+"p0 ++0+%p0 + 0  h*(  hx h c $(P@   r h S l(P@@  H h 0޽h ? 3fZX___i3___PPT10i.O{V+D=' = @B +-0 ,,7Tx,(  4)x   T #"*$TTeeT_p   <D,  ?"`   SR&D @`   <&  ?"`   eEnables new market, TBD @`   < U  ?"`   cBlood sugar screening @`   <F  ?"`   w)Glucose monitor for consumer applications** @`    <P  ?"`    Johnna Leddy  $ @`   <x\  ?"`   Znovation Gap 10   @`  <e  ?"`  UR & D @`6  <,`  ?"`  XUS Breast Cancer Therapeutics Mkt 2007: $3.1B, 9% (Applicable to several cancer markets)*2'Y @`  <z  ?"`   ]Clinic patients @`  <{  ?"`   8Cancer relevant therapeutics @`  <\  ?"`   XRay Hohl   @`  <T  ?"`  ~Terpenoid Therapeutics Gap 10 @`  <  ?"` UR & D @`  <ب  ?"` w)Est. US OLED Display Mkt 2007: $150M, 50%** @`  <L  ?"`  7Small digital electronics - cell phone, PDA, Blackberry88 @`  <p  ?"`   eOLED display technology @`  <ŋ  ?"`  bMarcus Wohlgenannt @`  <Nj  ?"` sOMR Sensors Gap 10  @`  <؋  ?"` VR & D  @`  <x  ?"` 2Est. US Ophthalmic Diagnostic Mkt 2007: $435M, 25%33 @`  <@  ?"`  3Lower-income clinics in diabetes-ridden populations44 @`  <  ?"`   dRetinal imaging system @`  <D  ?"`  `Michael Abramoff @`   <0   ?"` o iOptics Gap 10 @` ! <0  ?"` UR & D @` " <4  ?"` {-US Critical Care Equip Mkt 2007: $460M, 1.5% .. @` # <4&  ?"`  2Highly sensitive medical clinic applications (ICU)33 @` $ <d(  ?"`   r$Glucose monitor for ICU applications%% @` % <@9  ?"`  [ Mark Arnold   @` & <B  ?"` tASL Analytic Gap 10  @` - <DM  ?"` lStage24 @` . <lG  ?"` Ttl Market1 Size & Growth RateF  @` / <,a  ?"`  bMarket Addressed  @` 0 <c  ?"`   aInitial Product  @` 1 <|t  ?"`  YPI Lead  @` 2 <T}  ?"` YCompany  @`fB 3 6o ?`B 4 01 ?fB 5 6o ?  fB 6 6o ? `B 7 01 ? `B 8 01 ?   `B 9 01 ?  `B : 01 ? `B ; 01 ? fB < 6o ? `B = 01 ?`B > 01 ?`B ? 01 ?`B @ 01 ?   C 6t  HUI Gap Funded Projects ! D B,"` 0 ]1 Values describe revenue streams for entire market or market segment, not value of invention(^ ] % E B@"` GI a2 Stages: R & D, Product Definition, Product Development, Product Customer Testing, Product Sales(b a B  s *޽h ? 3fZX___i3___PPT10i.Q@l+D=' = @B + 0 @)K(  <p  B`n  K #""$TedB `n   <8   ?"`R` UR & D @`  <  ?"`R {-Est. US Cell-based Assay Mkt 2007: $560M, 15%.. @`  <h  ?"` R u'Basic science and pre-clinical research(( @`  <  ?"`R  _Custom cell lines @`  < Ì  ?"`R Y Greg Leno   @`   <͌  ?"` R RepGenix Gap 1 & 2 B   @`   <dnj  ?"``R UR & D @`   <`  ?"`R 3Product creates a new market; Est. Mkt 2007: $25M 44 @`   <h  ?"` R p"Pharma in pre-clinical development## @`   <(  ?"` R [ Human disease @`   <  ?"`R Z Mike Welsh   @`  <  ?"` R o TBD Gap 1 & 20  @` ' <  ?"``n  bProduct Definition @` ( <  ?"`n  q!(Market factors to be determined)"" @` ) <$  ?"` n  ~0New product development for interactive products11 @` * <-  ?"` n  W Simulator   @` + <L6  ?"`n  aKarim Abdel-Malek @` , <@  ?"` n  n Dynamo Gap 20  @` - <J  ?"`B` lStage24 @` . <U  ?"`B Ttl Market1 Size & Growth RateF  @` / <0O  ?"` B bMarket Addressed  @` 0 <|h  ?"`B  aInitial Product  @` 1 <q  ?"`B YPI Lead  @` 2 <pz  ?"` B YCompany  @`fB 3 6o ? B`B`B 4 01 ? `fB 5 6o ? n `n fB 6 6o ? B n `B 7 01 ?Bn `B 8 01 ?Bn `B 9 01 ? B n `B : 01 ?Bn `B ; 01 ?Bn fB < 6o ?`B`n `B A 01 ? R`R`B B 01 ? ` C 6  Z(& Gap Funded Projects ! D B܂"` 0 ]1 Values describe revenue streams for entire market or market segment, not value of invention(^ ] % E B"` GY a2 Stages: R & D, Product Definition, Product Development, Product Customer Testing, Product Sales(b a B  s *޽h ? 3fZX___i3___PPT10i.Q@l+D=' = @B +c 0 bb JJb(  RB  s *Dg P RB  s *Dg p @@x  c $7(P`      <.0  k#Company Patent Strategy & Execution,$ #GC:  3  :  3  :  3  :   3   :   3   :   3 {& :   3 &3 :   3 3A :  3 AN :  3 N[ :  3 [h :  3 hv :  3 v :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3  :  3   :  3   :  3 & :   3 &4 : ! 3 4A : " 3 AJ : # 3 JW : $ 3 Wd : % 3 dq : & 3 q : ' 3  : ( 3  : ) 3  : * 3  : + 3  : , 3  : - 3  : . 3  : / 3  : 0 3   1  BCDEFA @r 4 2 #  : 3 3  : 4 3  : 5 3 " : 6 3 "+ : 7 3 +8 : 8 3 8A : 9 3 AN : : 3 N\ : ; 3 \i : < 3 iv : = 3 v : > 3  : ? 3  : @ 3  : A 3  : B 3  : C 3  : D 3  : E 3  : F 3  : G 3  : H 3   : I 3   : J 3 ' : K 3 '4 : L 3 4A : M 3 AN : N 3 N\ : O 3 \i : P 3 iv : Q 3 v : R 3  : S 3  : T 3  : U 3  : V 3  : W 3  : X 3  : Y 3  : Z 3  : [ 3  : \ 3   : ] 3    : ^ 3  '  : _ 3 ' 4  : ` 3 4 A  : a 3 A J  : b 3 J W  : c 3 W e  : d 3 e r  : e 3 r   4 f #    g  BCDEF @  4 h # 7 i : i 3 7 i : j 3 7 i : k 3 7 i : l 3 7 i : m 3 7 i : n 3 7 i : o 3 7 i : p 3 7 i : q 3 7 i : r 3 7  i : s 3 7  i : t 3 7  i : u 3 7 ' i : v 3 7' 4 i : w 3 74 B i : x 3 7B O i : y 3 7O \ i : z 3 7\ i i : { 3 7i w i : | 3 7w i : } 3 7 i : ~ 3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7  i :  3 7 i :  3 7  i :  3 7 ' i :  3 7' 4 i :  3 74 B i :  3 7B O i :  3 7O X i :  3 7X e i :  3 7e r i :  3 7r i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i :  3 7 i l  S $ˍ7 i   :  3 7 i :  3 7  i    BC,DEF,z @:  f 4  #   :  3   :  3  # :  3 # 0 :  3 0 9 :  3